Dr.Reddy's launches Sevelamer Carbonate in US
Dr.Reddys Laboratories, in a filing to the exchanges on Thursday, informed that the company has launched Sevelamer Carbonate oral suspension in the US market.
"Dr.Reddy's Sevelamer Carbonate oral suspension is available in 0.8g and 2.4g packets in a count size of 90," the company added in a press note. "It is a therapeutic-equivalent/generic version of Renvela (sevelamer carbonate) but is an oral suspension that has been approved by the US Food and Drug Administration (USFDA)," the release added.
Suven Life Sciences secures product patents in Brazil and Eurasia
Suven Life Sciences Ltd said today that it has been granted a product patent from Brazil and Eurasia each for a new chemical entity used in the treatment of disorders associated with Neurodegenerative diseases. These product patents are valid through 2023 and 2034 respectively. We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally said Venkat Jasti, CEO of Suven.
L&T Construction wins contracts worth Rs2,357cr
Shares of Larsen and Toubro Ltd were trading flat on Thursday afternoon even as the company announced contract wins worth Rs2,357cr. The water and effluent treatment and transportation infrastructure businesses of Larsen and Toubro Ltd have secured a build and design order worth Rs1,281cr.
The scope of the contract includes investigation, designing and construction of roads, bridges, stormwater drains, culverts, water supply systems, sewerage systems, STP, utility ducts for power and ICT, reuse waterlines and avenue plantation. These should be compatible with trunk infrastructure in layouts for land pooling schemes for the villages of Kurunegala, Nidamarru in Zone 12A area at Amravati Capital City, Andhra Pradesh. This order is in continuation of the orders received earlier at Amravati Capital City, Andhra Pradesh.
Sun Pharma unit gets preliminary injunctive relief in US Court
DUSA Pharmaceuticals, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries announced that it has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG (together known as Biofrontera) from using DUSA confidential and proprietary trade secret information.
Dr.Reddys Laboratories, in a filing to the exchanges on Thursday, informed that the company has launched Sevelamer Carbonate oral suspension in the US market.
"Dr.Reddy's Sevelamer Carbonate oral suspension is available in 0.8g and 2.4g packets in a count size of 90," the company added in a press note. "It is a therapeutic-equivalent/generic version of Renvela (sevelamer carbonate) but is an oral suspension that has been approved by the US Food and Drug Administration (USFDA)," the release added.
Suven Life Sciences secures product patents in Brazil and Eurasia
Suven Life Sciences Ltd said today that it has been granted a product patent from Brazil and Eurasia each for a new chemical entity used in the treatment of disorders associated with Neurodegenerative diseases. These product patents are valid through 2023 and 2034 respectively. We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally said Venkat Jasti, CEO of Suven.
L&T Construction wins contracts worth Rs2,357cr
Shares of Larsen and Toubro Ltd were trading flat on Thursday afternoon even as the company announced contract wins worth Rs2,357cr. The water and effluent treatment and transportation infrastructure businesses of Larsen and Toubro Ltd have secured a build and design order worth Rs1,281cr.
The scope of the contract includes investigation, designing and construction of roads, bridges, stormwater drains, culverts, water supply systems, sewerage systems, STP, utility ducts for power and ICT, reuse waterlines and avenue plantation. These should be compatible with trunk infrastructure in layouts for land pooling schemes for the villages of Kurunegala, Nidamarru in Zone 12A area at Amravati Capital City, Andhra Pradesh. This order is in continuation of the orders received earlier at Amravati Capital City, Andhra Pradesh.
Sun Pharma unit gets preliminary injunctive relief in US Court
DUSA Pharmaceuticals, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries announced that it has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG (together known as Biofrontera) from using DUSA confidential and proprietary trade secret information.
The announcement made after market hours on Wednesday.
DUSA had filed a lawsuit against the Biofrontera defendants earlier this year in the US District Court for the District of Massachusetts. The lawsuit alleges trade secret misappropriation and patent infringement of DUSA photodynamic therapy (PDT) patents, US 9,723,991 and US 8,216,289, covering DUSA product, LEVULAN KERASTICK (aminolevulinic acid HCl) for a topical solution, 20% used with DUSA BLU-U Blue Light Photodynamic Therapy Illuminator.
Bajaj Auto to enter e-vehicles space by 2020
Bajaj Auto is looking to enter the electric vehicle space by 2020 with two and three-wheeler products, said Rajiv Bajaj, Managing Director of the company. Bajaj added that the company is aiming at 20-25% market share going forward from its current 15-20% share over the next 12 months. When asked if the next few months look difficult because of the global environment, he answered that the scenario, in fact, looked interesting and exciting on back of some interesting trends that are emerging.
Financial Advisory Company in Indore, Stock Advisory Company in Indore , Equity Tips , Free Trading Tips , MCX Tips , sebi registered advisory company , Intraday stock tips , Free commodity tips
0 comments:
Post a Comment